Table 2 Comparison of baseline data, hematological parameters and coronary angiography data in elevated FBG group and control group
Variables | Elevated FBG group (n = 589) | Normal FBG group(n = 369) | P value |
|---|---|---|---|
Gender(man) | 433 (73.5%) | 303 (82.1%) | 0.002* |
Age | 62.91 ± 13.01 | 61.72 ± 13.84 | 0.185 |
Height(cm) | 166.77 ± 7.64 | 166.70 ± 7.20 | 0.087 |
Weight(kg) | 69.02 ± 12.20 | 68.15 ± 11.73 | 0.319 |
BMI(kg/m2) | 24.77 ± 3.70 | 24.09 ± 3.71 | 0.012* |
SBP(mmHg) | 127.08 ± 23.18 | 125.34 ± 19.14 | 0.235 |
DBP(mmHg) | 76.89 ± 15.05 | 76.44 ± 13.84 | 0.467 |
Hypertension | 349 (59.3%) | 202 (54.7%) | 0.169 |
Diabetes | 242 (41.1%) | 20 (5.4%) | < 0.001* |
Previous MI | 15 (2.5%) | 7 (1.9%) | 0.514 |
Cerebral infarction, | 86 (14.6%) | 16 (4.3%) | < 0.001* |
CKD | 54 (9.2%) | 25 (6.8%) | 0.190 |
Smoking | 283 (48.0%) | 216 (58.5%) | 0.002* |
Killip grade | |||
 I grade | 367 (62.3%) | 293 (79.4%) | < 0.001* |
 II grade | 103 (17.5%) | 51 (13.8%) | 0.133 |
 III grade | 9 (1.5%) | 2 (0.5%) | 0.163 |
 IV grade | 99 (16.8%) | 34 (9.2%) | < 0.001* |
TNI P50(P25-P75)(ng/ml) | 17 (3.98–25) | 11 (2.3–25) | 0.002* |
Myo P50(P25-P75) (ng/ml) | 500 (219.75–900) | 500 (206.25–900) | 0.016* |
CK-MB P50(P25-P75)(ng/ml) | 80 (36.45–297) | 80 (37.5–246.5) | 0.260 |
BNP P50(P25-P75) (pg/ml) | 173 (49.75–587.5) | 112 (41.45–347.5) | 0.001* |
WBC (*10^9/L) | 12.29 ± 4.45 | 10.47 ± 2.94 | < 0.001* |
Hb (g/L) | 134.5 ± 23.11 | 135.99 ± 20.71 | 0.066 |
PLT (*10^9/L) | 209.87 (160.3–268.3) | 201.7 (170.4–259.2) | 0.051 |
RBG(mmol/L) | 11.25 (9.3–16.5) | 7.22 (6.8–10.0) | < 0.001* |
ALT P50(P25-P75)IU/L) | 48 (33–79) | 39 (29–59) | < 0.001* |
AST P50(P25-P75) (IU/L) | 145 (60–219) | 171 (89–309) | < 0.001* |
Scr P50(P25-P75) (μmol/L) | 81 (67–98) | 80 (72–91) | 0.862 |
eGFR P50(P25-P75) (ml/min/1.73m2) | 80.9 (62.22–97.88) | 81.7 (69.2–96.2) | 0.704 |
UA(μmol/L) | 376.41 (280.3–390.3.2) | 365.35 (249.5–378.4) | 0.152 |
FBG(mmoL/L) | 9.79 ± 2.67 | 5.22 ± 0.52 | < 0.001* |
TG(mmoL/L) | 1.83 (1.28–2.56) | 1.64 (0.89–2.06) | 0.051 |
TC(mmoL/L) | 4.46 (4.13–5.84) | 4.42 (4.02–5.73) | 0.667 |
HDL-c(mmoL/L) | 1.12 (0.83–1.46) | 1.07 (0.95–1.47) | 0.046* |
LDL-c(mmoL/L) | 2.77 (2.19–3.07) | 2.80 (2.26–3.26) | 0.682 |
LVEF (%) | 0.53 ± 0.38 | 0.68 ± 0.34 | < 0.001* |
Aspirin | 581 (98.6%) | 364 (98.6%) | 0.997 |
Clopidogrel | 61 (10.4%) | 55 (14.9%) | 0.028* |
Ticagrelor | 528 (89.6%) | 314 (85.1%) | 0.028* |
ACEI/ARB | 277 (47.0%) | 205 (55.6%) | 0.01* |
β-blocker | 494 (83.9%) | 300 (81.3%) | 0.304 |
Statin | 586 (99.5%) | 367 (99.5%) | 0.946 |
CCB | 30 (5.1%) | 30 (8.1%) | 0.059 |
Furosemide | 174 (29.5%) | 75 (20.3%) | 0.002* |
Antisterone | 172 (29.2%) | 77 (20.9%) | 0.004* |
IABP | 51 (8.7%) | 12 (3.3%) | 0.001* |
CABG | 10 (17.1%) | 3 (0.8%) | 0.249 |
Coronary lesions | |||
 Single vessel lesion | 101 (29.0%) | 135 (36.6%) | < 0.001* |
 Double vessel lesions | 171(%) | 115 (31.2%) | 0.483 |
 Triple vessel lesions | 284 (48.2%) | 152 (41.2%) | 0.034* |
Number of stents | |||
 Single stent | 340 (57.7%) | 242 (65.6%) | 0.015* |
 Two or more stents | 124 (21.1%) | 53 (14.4%) | 0.009* |
 Left main lesion | 75 (12.7%) | 24 (6.5%) | 0.002* |